FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 180 filers reported holding FATE THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 1.39 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $156 | +147.6% | 73,642 | +569.5% | 0.00% | +100.0% |
| Q1 2023 | $63 | -100.0% | 11,000 | -15.9% | 0.00% | -66.7% |
| Q2 2022 | $324,000 | -92.0% | 13,076 | -87.5% | 0.00% | -90.0% |
| Q1 2022 | $4,059,000 | -83.5% | 104,705 | -75.1% | 0.03% | -77.6% |
| Q4 2021 | $24,585,000 | +632.6% | 420,190 | +642.2% | 0.13% | +737.5% |
| Q3 2021 | $3,356,000 | -27.1% | 56,614 | +6.7% | 0.02% | -23.8% |
| Q2 2021 | $4,606,000 | +215.7% | 53,071 | +199.9% | 0.02% | +162.5% |
| Q1 2021 | $1,459,000 | +456.9% | 17,699 | +514.8% | 0.01% | +700.0% |
| Q4 2020 | $262,000 | -91.5% | 2,879 | -96.3% | 0.00% | -95.0% |
| Q3 2020 | $3,089,000 | +1945.7% | 77,271 | +1651.8% | 0.02% | +1900.0% |
| Q2 2020 | $151,000 | -73.3% | 4,411 | -82.7% | 0.00% | -80.0% |
| Q1 2020 | $565,000 | +234.3% | 25,435 | +163.9% | 0.01% | +150.0% |
| Q1 2019 | $169,000 | +302.4% | 9,637 | -9.1% | 0.00% | – |
| Q3 2017 | $42,000 | – | 10,596 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |